A high level of sclerostin in chronic kidney disease patients is associated with the pathogenesis of bone disorders such as an increased fracture risk and correlates positively with serum 1,25(OH)2D3, phosphorus, and TNF-α, indicating a decrease in the bone turnover rate [187,188]. Here, SOST is linked to chronic kidney disease.